Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

NCT07108985 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Hyperglycemia
Insulin Resistance

Interventions

DRUG: Sitagliptin 100 mg
DRUG: Sitagliptin 100 mg + Dapagliflozin 10 mg
DRUG: Sitagliptin 100 mg + Dapagliflozin 10 mg
DRUG: Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg

Sponsor

Yonsei University